

## Who can administer

### POTASSIUM phosphate

- **Infusions prepared at ward level using ampoules**

- May be administered by registered competent doctor or nurse/midwife, PROVIDED the **guidelines below** (in Methods of Administration) have been adhered to

## Important information

- **There are two separate monographs for IV phosphate- sodium phosphate or potassium phosphate- please ensure you are using the correct monograph**
- Caution with rate of administration (due to potassium content)
- Suggest: **Senior doctor review** before administration of intravenous phosphate, as it's use **can be dangerous**
  - **Caution:** the response to any given dose cannot be predicted, and IV use can cause hypocalcaemia (tetany), calcium-phosphate precipitation in the kidneys, and fatal arrhythmias (ref 1)
- Patients with **HYPocalcaemia** should have their calcium corrected before replacing phosphate (ref 5)
- Patients with **severe HYPERcalcaemia** who require phosphate replacement: seek specialist advice (ref 4)
- **Renal impairment:** Requires dose adjustment- see below
- **Give in a dedicated line** as it may precipitate with other drugs

## Available preparations

| Phosphate salt   | Volume | Phosphate content per vial/ampoule/bag | Sodium content per vial/ampoule/bag | Potassium content per vial/ampoule/bag |
|--|--------|--|-------------------------------------|--|
| Potassium phosphate <b>ampoule</b> (Braun)   | 20ml   | 12mmol                                 | nil                                 | 20mmol                                 |
| Phosphate polyfusor pre-mixed <b>bag</b> - very severe hypophosphataemia. <b>Supplied only on request.</b> | 500ml  | 50mmol                                 | 81mmol                              | 9.5mmol                                |

## Reconstitution

Already in solution

**Ampoules should be diluted further prior to administration**

Â

### Addition of potassium phosphate concentrate to infusion bags

- Preparation must be done **jointly by a doctor and a nurse** in the clinic room.
- Both the Controlled Drug register, and the Additive label **must be signed** by the SAME doctor and

nurse

- UNUSED ampoules must immediately be returned to the CD press and signed back into the CD register by the SAME doctor and nurse
- Clearly over-label the infusion bag to reflect the TOTAL amount of mmol of potassium phosphate
- After adding potassium phosphate concentrate to an infusion bag, squeeze and invert bag aÂ MINIMUMÂ of ten times to avoid inadvertent administration of a toxic bolusÂ

## Infusion fluids

Sodium chloride 0.9% (preferred)Â

Glucose 5% may also be used if clinically appropriate

## Methods of intravenous administration

### Intermittent intravenous infusion (using an electronically controlled infusion device)

- Administer as per guidelines below

## Dose in adults

**Table 1: Guidance on route given below but clinical judgement is always requiredÂ<sup>(ref 1)</sup>**

| Route of administration     | Phosphate level  |
|-----------------------------|--|
| Oral/enteral replacement    | PREFERRED if >0.32mmol/L and asymptomaticÂ<br>or<br>if level >0.48mmol/LÂ and symptomaticÂ         |
| Intravenous route preferred | <0.32mmol/L<br>or<br><0.48mmol and symptomatic<br>or<br>if unable to tolerate oral supplementation |

Â

**Table 2: POTASSIUM PHOSPHATEÂ via peripheral line**

- Consider ONLY IF co-existing hypokalaemiaÂ
- Preferable to treat hypophosphataemia and hypokalaemia separately using two individual infusion bags - rather than using Potassium phosphate vial at all.Â Â This allows for the greatest amount of flexibility in the doses of both electrolytes
- It isÂ difficult to provide concrete guidelines for the treatment of severe hypophosphataemia as regimens vary greatly across hospitals in the UK and Ireland - **we have tried to provide guidelines belowÂ but clinical judgment is always requiredÂ**
- Use caution when interpreting phosphate levels.Â Changes in phosphate levels may be transient - treating **underlying causesÂ** may be sufficient to correct level.Â **Review medications** which may contribute e.g. sevelamar, antacids, diureticsÂ<sup>(ref 5)</sup>
- The response to any given dose cannot be predicted, and IV use can cause hypocalcaemia (tetany), calcium-phosphate precipitation in the kidneys, and fatal arrhythmias<sup>(ref 1)</sup>
- **Prescribe dose in terms of phosphate dose required and then the phosphate salt required**
  - egÂ Â '12mmol phosphate as potassium phosphate'

|   |  |                       |                               |
|---|--|-----------------------|-------------------------------|
| <b>Gentle replacement</b>                           | <b>Dose:</b> 9mmol phosphate over 12 hours, and repeat as necessary <sup>(ref 2,3)</sup>   |                       |                               |
| <b>More individualised dosing<sup>(ref 1)</sup></b> | <b>Level (mmol/L)</b>  | <b>Phosphate dose</b> | <b>Maximum initial dose</b>   |
|   | less than 0.32   | 0.4mmol/kg            | 48mmol <sup>Â</sup> phosphate |
|   | 0.33 to 0.44   | 0.3mmol/kg            | 30mmol <sup>Â</sup> phosphate |
| <b>Preparation</b>                                  | >0.45  | 0.2mmol/kg            | 20mmol <sup>Â</sup> phosphate |
|   | <b>Doses up to 24mmol phosphate (40mmol potassium)<sup>Â</sup></b> <ul style="list-style-type: none"> <li>• Add to 500mL infusion fluid</li> </ul> <b>Doses 25 to 48mmol phosphate (40<sup>(approx)</sup> to 80mmol potassium)<sup>Â</sup></b> <ul style="list-style-type: none"> <li>• Add to 1000mL infusion fluid</li> <li>• For fluid restricted patients <ul style="list-style-type: none"> <li>◦ May be added to less volume <b>provided the final concentration does not exceed 40mmol POTASSIUM per 500mL</b></li> </ul> </li> </ul> |                       |                               |
| <b>Administration</b>                               | <ul style="list-style-type: none"> <li>• Administer the required dose<sup>Â</sup> <b>over 12 hours</b></li> <li>• <b>May administer more quickly<sup>Â</sup> - however cannot exceed a rate of administration of the POTASSIUM element of 10mmol/hour</b> <ul style="list-style-type: none"> <li>◦ Doses of 36mmol phosphate or less may be administered over minimum 6 hours if clinically appropriate</li> <li>◦ Doses greater than 36mmol phosphate MUST be administered over minimum 8 to 12 hours</li> </ul> </li> </ul>                |                       |                               |
| <b>Renal impairment</b>                             | Use with great caution, consider specialist advice<br>Generally avoid in severe renal impairment <sup>(ref 6)</sup>  |                       |                               |
| <b>Critical care/Fluid restriction</b>              | Higher doses and rates may apply in the Critical Care setting  |                       |                               |
| <b>Polyfusor</b>                                    | Available in Critical care areas- note however- only contains 9.5mmol potassium per polyfusor <sup>Â</sup>   |                       |                               |
| <b>Repeated doses</b>                               | <ul style="list-style-type: none"> <li>• May require repeat infusions over subsequent days.</li> <li>• Usual maximum is 50mmol phosphate per 24 hours</li> </ul>   |                       |                               |
| <b>Switch to oral route</b>                         | Consider switch to oral route once level >0.48mmol/L   |                       |                               |

Â

### **Renal impairment**

- Use reduced doses with caution- see tables above

## **Monitoring**

- Monitor the following electrolytes every 6 to 12 hours: phosphate, calcium, potassium, sodium, magnesium
- Monitor fluid balance and blood pressure
- Monitor ECG

## **Storage**

- Potassium phosphate ampoules are treated as a **controlled drug in GUHs** (as it is a potassium concentrate as well as containing phosphate). The routine supply of potassium phosphate is restricted

to designated wards which are likely to be caring for critically ill patients

- Phosphate Polyfusor is NOT treated as a controlled drug
- Store below 25°C

## References

1. Uptodate. Hypophosphataemia: Evaluation and Treatment March 2024. Accessed online 23/01/2025
2. Martindale- accessed online 23/01/2025
3. BNF- accessed online 23/01/2025
4. UpToDate Potassium Phosphate monograph - accessed March 2025
5. Maidstone and Tunbridge Wells NHS Trust 'Treatment of acute hypophosphataemia in adults. Review date August 2027
6. Local specialist opinion - email on file 25/06/2025

These local guidelines were also consulted in the preparation of guide (to try and create a consensus from different sources)

- Grampian staff guideline for the management of hypophosphataemia in adults July 2024
- Worcestershire acute hospitals NHS Trust 'guideline for the treatment of hypophosphataemia in adults, March 2023
- Liverpool University Hospitals NHS TrustÂ
- UKMI Leeds hospital 'How is acute hypophosphataemia treated in adults
- Adults Therapeutic Handbook (NHS Greater Glasgow and Clyde), May 2023 Management of hypophosphataemia